ZA201701069B - Pyrrolopyrimidine derivatives as nr2b nmda receptor antagonists - Google Patents
Pyrrolopyrimidine derivatives as nr2b nmda receptor antagonistsInfo
- Publication number
- ZA201701069B ZA201701069B ZA2017/01069A ZA201701069A ZA201701069B ZA 201701069 B ZA201701069 B ZA 201701069B ZA 2017/01069 A ZA2017/01069 A ZA 2017/01069A ZA 201701069 A ZA201701069 A ZA 201701069A ZA 201701069 B ZA201701069 B ZA 201701069B
- Authority
- ZA
- South Africa
- Prior art keywords
- receptor antagonists
- nmda receptor
- pyrrolopyrimidine derivatives
- nr2b nmda
- nr2b
- Prior art date
Links
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 title 1
- 108010054200 NR2B NMDA receptor Proteins 0.000 title 1
- 150000004944 pyrrolopyrimidines Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462050692P | 2014-09-15 | 2014-09-15 | |
| PCT/US2015/050267 WO2016044323A1 (en) | 2014-09-15 | 2015-09-15 | Pyrrolopyrimidine derivatives as nr2b nmda receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201701069B true ZA201701069B (en) | 2019-07-31 |
Family
ID=54293326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2017/01069A ZA201701069B (en) | 2014-09-15 | 2017-02-13 | Pyrrolopyrimidine derivatives as nr2b nmda receptor antagonists |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US9567341B2 (enExample) |
| EP (1) | EP3194403B1 (enExample) |
| JP (1) | JP6612331B2 (enExample) |
| KR (1) | KR102569031B1 (enExample) |
| CN (1) | CN106715435B (enExample) |
| AU (1) | AU2015317886A1 (enExample) |
| CA (1) | CA2957898C (enExample) |
| DK (1) | DK3194403T3 (enExample) |
| ES (1) | ES2723436T3 (enExample) |
| IL (1) | IL251027A0 (enExample) |
| MX (1) | MX2017002775A (enExample) |
| RU (1) | RU2017107558A (enExample) |
| SG (1) | SG11201701853YA (enExample) |
| WO (1) | WO2016044323A1 (enExample) |
| ZA (1) | ZA201701069B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3152213B1 (en) * | 2014-06-04 | 2018-10-31 | Rugen Holdings (Cayman) Limited | Difluoroethylpyridine derivatives as nr2b nmda receptor antagonists |
| CA2957898C (en) | 2014-09-15 | 2023-02-21 | Rugen Holdings (Cayman) Limited | Pyrrolopyrimidine derivatives as nr2b nmda receptor antagonists |
| US10221182B2 (en) | 2015-02-04 | 2019-03-05 | Rugen Holdings (Cayman) Limited | 3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists |
| US10584127B2 (en) | 2015-06-01 | 2020-03-10 | Rugen Holdings (Cayman) Limited | 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists |
| US10487055B2 (en) | 2016-06-01 | 2019-11-26 | Rhode Island Board Of Education | Diindole compounds useful in treatment of nervous system disorders |
| WO2018098128A1 (en) | 2016-11-22 | 2018-05-31 | Rugen Holdings (Cayman) Limited | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders |
| MA51020B1 (fr) * | 2017-12-08 | 2021-10-29 | Boehringer Ingelheim Int | Composés imidazopyridiniques et leur utilisation comme médicament |
| EP3870292A4 (en) | 2018-10-26 | 2022-11-09 | The Research Foundation for The State University of New York | COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA |
| EP4074317A1 (en) | 2021-04-14 | 2022-10-19 | Bayer AG | Phosphorus derivatives as novel sos1 inhibitors |
| CN117185897A (zh) * | 2023-08-31 | 2023-12-08 | 上海泰坦科技股份有限公司 | 一种二氟甲基卤苯的合成方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE215072T1 (de) | 1995-08-11 | 2002-04-15 | Pfizer | (1s,2s)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4- phenylpiperidin-1-yl)-1-propanol-methansulfonat trihydrat |
| US6476041B1 (en) | 1999-10-29 | 2002-11-05 | Merck & Co., Inc. | 1,4 substituted piperidinyl NMDA/NR2B antagonists |
| HU227197B1 (en) | 2000-10-24 | 2010-10-28 | Richter Gedeon Nyrt | Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them |
| WO2002068409A1 (en) | 2001-02-23 | 2002-09-06 | Merck & Co., Inc. | N-substituted nonaryl-heterocyclic nmda/nr2b antagonists |
| US7592360B2 (en) | 2003-06-04 | 2009-09-22 | Merck & Co., Inc. | 3-fluoro-piperidines as NMDA/NR2B antagonists |
| ATE403651T1 (de) | 2003-06-04 | 2008-08-15 | Merck & Co Inc | 3-fluoro-piperidine als nmda/nr2b antagonisten |
| EP1656379B1 (en) | 2003-08-15 | 2007-01-10 | Merck & Co., Inc. | 4-cycloalkylaminopyrazolo pyrimidine nmda/nr2b antagonists |
| WO2005102390A2 (en) | 2004-04-22 | 2005-11-03 | Pfizer Japan, Inc. | Combinations comprising alpha-2-delta ligands and nmda receptor antagonists |
| WO2006017409A2 (en) | 2004-08-03 | 2006-02-16 | Merck & Co., Inc. | 1,3-disubstituted heteroaryl nmda/nr2b antagonists |
| CN101084191A (zh) | 2004-12-22 | 2007-12-05 | 默克公司 | 用于制备取代哌啶类化合物的方法 |
| WO2006113471A2 (en) * | 2005-04-19 | 2006-10-26 | Merck & Co., Inc. | N-alkyl-azacycloalkyl nmda/nr2b antagonists |
| CN101233138A (zh) | 2005-07-29 | 2008-07-30 | 辉瑞产品公司 | 吡咯并[2，3-d]嘧啶衍生物、其中间体和合成方法 |
| WO2007061868A2 (en) | 2005-11-17 | 2007-05-31 | Trustees Of Tufts College | Treatment of stereotypic, self-injurious and compulsive behaviors using specific serotonin reuptake inhibitors and antagonists of nmda receptors |
| WO2007099828A1 (ja) | 2006-02-23 | 2007-09-07 | Shionogi & Co., Ltd. | 環式基で置換された含窒素複素環誘導体 |
| CA2673918C (en) | 2006-12-27 | 2015-02-17 | Sanofi-Aventis | Substituted isoquinoline and isoquinolinone derivatives |
| WO2010015637A1 (en) | 2008-08-06 | 2010-02-11 | Novartis Ag | New antiviral modified nucleosides |
| US20130096115A1 (en) | 2009-12-28 | 2013-04-18 | Afraxis, Inc. | Methods for treating autism |
| AU2011239966B2 (en) | 2010-04-16 | 2014-05-08 | Ac Immune S.A. | Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins |
| EP2580213A4 (en) | 2010-06-09 | 2013-12-25 | Afraxis Holdings Inc | 8- (HETEROARYLMETHYL) PYRIDO [2,3-D] PYRIMIDIN-7 (8H) -ONES FOR THE TREATMENT OF CNS DISORDERS |
| WO2011159945A2 (en) | 2010-06-16 | 2011-12-22 | Afraxis, Inc. | Methods for treating neurological conditions |
| US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| EP2683716A1 (en) | 2011-03-11 | 2014-01-15 | Glaxo Group Limited | Pyrido[3,4-b]pyrazine derivatives as syk inhibitors |
| EP2713722B1 (en) | 2011-05-31 | 2017-03-15 | Receptos, LLC | Novel glp-1 receptor stabilizers and modulators |
| ES2627541T3 (es) | 2012-04-20 | 2017-07-28 | Ucb Pharma, S.A. | Métodos para tratar la enfermedad de Parkinson |
| AU2014212501A1 (en) | 2013-01-29 | 2015-07-30 | Aptinyx, Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
| WO2015171770A1 (en) | 2014-05-06 | 2015-11-12 | Northwestern University | Combinations of nmdar modulating compounds |
| EP3152213B1 (en) | 2014-06-04 | 2018-10-31 | Rugen Holdings (Cayman) Limited | Difluoroethylpyridine derivatives as nr2b nmda receptor antagonists |
| CA2957898C (en) | 2014-09-15 | 2023-02-21 | Rugen Holdings (Cayman) Limited | Pyrrolopyrimidine derivatives as nr2b nmda receptor antagonists |
| WO2016049048A1 (en) | 2014-09-22 | 2016-03-31 | Rugen Holdings (Cayman) Limited | Treatment of anxiety disorders and autism spectrum disorders |
| WO2016100349A2 (en) | 2014-12-16 | 2016-06-23 | Rugen Holdings (Cayman) Limited | Bicyclic azaheterocyclic compounds as nr2b nmda receptor antagonists |
| US10221182B2 (en) | 2015-02-04 | 2019-03-05 | Rugen Holdings (Cayman) Limited | 3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists |
| US10584127B2 (en) | 2015-06-01 | 2020-03-10 | Rugen Holdings (Cayman) Limited | 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists |
| WO2018098128A1 (en) | 2016-11-22 | 2018-05-31 | Rugen Holdings (Cayman) Limited | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders |
-
2015
- 2015-09-15 CA CA2957898A patent/CA2957898C/en active Active
- 2015-09-15 ES ES15779059T patent/ES2723436T3/es active Active
- 2015-09-15 AU AU2015317886A patent/AU2015317886A1/en not_active Abandoned
- 2015-09-15 SG SG11201701853YA patent/SG11201701853YA/en unknown
- 2015-09-15 US US14/855,010 patent/US9567341B2/en active Active
- 2015-09-15 JP JP2017514306A patent/JP6612331B2/ja active Active
- 2015-09-15 RU RU2017107558A patent/RU2017107558A/ru not_active Application Discontinuation
- 2015-09-15 EP EP15779059.3A patent/EP3194403B1/en active Active
- 2015-09-15 KR KR1020177010056A patent/KR102569031B1/ko active Active
- 2015-09-15 DK DK15779059.3T patent/DK3194403T3/en active
- 2015-09-15 MX MX2017002775A patent/MX2017002775A/es unknown
- 2015-09-15 CN CN201580049617.5A patent/CN106715435B/zh active Active
- 2015-09-15 WO PCT/US2015/050267 patent/WO2016044323A1/en not_active Ceased
-
2017
- 2017-02-09 US US15/428,321 patent/US9968610B2/en active Active
- 2017-02-13 ZA ZA2017/01069A patent/ZA201701069B/en unknown
- 2017-03-08 IL IL251027A patent/IL251027A0/en unknown
-
2018
- 2018-04-24 US US15/961,553 patent/US10420768B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2957898A1 (en) | 2016-03-24 |
| AU2015317886A1 (en) | 2017-03-09 |
| CA2957898C (en) | 2023-02-21 |
| SG11201701853YA (en) | 2017-04-27 |
| IL251027A0 (en) | 2017-04-30 |
| BR112017004868A2 (pt) | 2017-12-12 |
| DK3194403T3 (en) | 2019-04-15 |
| US10420768B2 (en) | 2019-09-24 |
| WO2016044323A1 (en) | 2016-03-24 |
| MX2017002775A (es) | 2017-08-10 |
| KR102569031B1 (ko) | 2023-08-22 |
| JP2017526724A (ja) | 2017-09-14 |
| EP3194403B1 (en) | 2019-02-06 |
| ES2723436T3 (es) | 2019-08-27 |
| US9567341B2 (en) | 2017-02-14 |
| US20180303834A1 (en) | 2018-10-25 |
| US20170209449A1 (en) | 2017-07-27 |
| RU2017107558A (ru) | 2018-10-18 |
| CN106715435B (zh) | 2019-10-01 |
| US20160075713A1 (en) | 2016-03-17 |
| KR20170049602A (ko) | 2017-05-10 |
| US9968610B2 (en) | 2018-05-15 |
| CN106715435A (zh) | 2017-05-24 |
| JP6612331B2 (ja) | 2019-11-27 |
| EP3194403A1 (en) | 2017-07-26 |
| RU2017107558A3 (enExample) | 2019-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL252257A0 (en) | Insulin receptor partial agonists | |
| GB2545368B (en) | Diversion-resistant opioid formulations | |
| GB201514875D0 (en) | Receptor | |
| GB201518816D0 (en) | Receptor | |
| IL251027A0 (en) | History of pyrrolopyrimidines as nr2b nmda receptor antagonists | |
| EP3137074A4 (en) | Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto | |
| GB201405337D0 (en) | Feed unit | |
| GB2531940B (en) | Process for preparing methotrexate formulation | |
| EP3193852A4 (en) | Nmda receptor antagonists for treating gaucher disease | |
| SG11201605618WA (en) | Selective nr2b antagonists | |
| IL256496B (en) | 5–ht2 blockers | |
| ZA201607284B (en) | Folding hopper | |
| EP3253761A4 (en) | 3,3-difluoro-piperidine derivatives as nr2b nmda receptor antagonists | |
| ZA201605243B (en) | Ethynyl derivatives | |
| EP3154956A4 (en) | Glucagon antagonists | |
| EP3136858A4 (en) | Guanosine as an immunepotentiator mediated through toll receptors | |
| SI3484889T1 (sl) | Derivati etinila | |
| EP3142666A4 (en) | 5-ht4 receptor agonist for gastroparesis | |
| TWM490258U (en) | Folding structure for furniture | |
| ZA201605808B (en) | Process for preparing an endothelin receptor antagonist | |
| HK1231053A1 (en) | Glucagon antagonists | |
| HK1225025A1 (en) | Selective nr2b antagonists | |
| EP3162366A4 (en) | Sweetness receptor antagonist | |
| HK1236210A1 (en) | Insulin receptor partial agonists | |
| TWM489280U (en) | Vibrator table structure |